Company Overview of MiniVax, Inc.
MiniVax, Inc. engages in the research and development of vaccines and therapeutics for the treatment and prevention of opportunistic fungal infections. It focuses on developing solutions for the indication Pneumocystis pneumonia (PCP), such as PCP-Antibody, a monoclonal antibody for the treatment of PCP; PCP-Vaccine, a vaccine that promotes the development of long-term anti-Pneumocystis antibodies for the prevention of PCP; and PCP-Diagnostic, a diagnostic solution for the detection of a Pneumocystis infection. The company was incorporated in 2010 and is based in New Orleans, Louisiana.
1441 Canal Street
New Orleans, LA 70112
Founded in 2010
Key Executives for MiniVax, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact MiniVax, Inc., please visit www.minivaxcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.